Image: Pexels | Written by: Medical Companion Travel Content Team
Original articles, please do not reprint without permission
As a class of immune-mediated, idiopathic, chronic inflammatory diseases of the large intestine, malarial colitis can cause patients to have persistent mucosal inflammation, extending from the rectum to the colon to varying degrees. The main clinical features of ulcerative colitis are fecal incontinence, bloody diarrhea, urgency, abdominal pain, tenesmus, and rectal bleeding.
And the condition of such diseases also varies from person to person, some patients are chronic refractory diseases, some patients are static diseases, and in some specific conditions, they can also cause complications, such as cancer. The active ingredient in uppatinib (Rinvoq) is upadacitinib, a reversible, orally selective JAK1 inhibitor developed by AbbVie Pharmaceuticals that can play an important role in many types of inflammatory conditions. Today, let's take a look at the drug of uppatinib!
AbbVie recently announced that the U.S. Food and Drug Administration (FDA) has approved uptopatinib (Rinvoq) for the treatment of adult patients with moderate to severely active ulcerative colitis (UC) who are inadequate or intolerant to one or more tumor necrosis factor (TNF) blockers.
With this approval, it indicates the first indication of uppatinib in the field of gastroenterology. Rinvoq is an oral, once-daily, selective, reversible JAK inhibitor developed to treat a variety of immune-mediated inflammatory diseases. Upatinib was first approved in 2019 and is currently approved for 4 therapeutic indications in the areas of gastrointestinal diseases, skin diseases and rheumatism. It has caused quite a stir in the medical community.
What are the precautions when using upatinib?
The first item: malignant tumors
When starting treatment with upatinib, patients need to first consider the risks and benefits of upatinib.
Second item: gastrointestinal perforation
Use uppatinib with caution if there is a risk of gastrointestinal perforation at its own time.
Item 3: Embryonic-fetal toxicity
According to previous animal research experiments, uppatinib may cause harm to the embryo-fetus, so it is necessary to inform in advance of the risks of female patients with reproductive potential and the potential harm to the fetus, such patients need to take effective contraception.
Item 4: Severe infection
In patients with active infection, if the infection is very severe, uppatinib needs to be discontinued.
Fifth item: thrombosis
The use of uppatinib may increase the risk of thrombosis, so patients need to consider the risks and benefits, assess the patient's thrombosis type in a timely manner, and take effective treatment.
Item 6: Laboratory monitoring
Due to potential changes in lipids, liver enzymes, hemoglobin, neutrophils, lymphocytes, regular laboratory monitoring is recommended.
Upatinib listing history in China
In February 2022, the State Food and Drug Administration approved the listing of uppatinib, which can be applied to the treatment of moderate to severe, refractory atopic dermatitis in adults and adolescents over 12 years of age. This approval means that uppatinib has been approved for the first indication in China. In addition, uppatinib is also the first approved JAK oral inhibitor for the treatment of atopic dermatitis in China, marking the beginning of a new era of oral targeted therapy for atopic dermatitis in China.
From the above we can see that uppatinib can not only treat ulcerative colitis, but also atopic dermatitis and other types of inflammation. This is an important choice for all kinds of inflammatory patients.